dc.creatorMorales, Javier Octavio
dc.creatorMcConville, Jason Thomas
dc.date.accessioned2019-03-15T16:06:42Z
dc.date.available2019-03-15T16:06:42Z
dc.date.created2019-03-15T16:06:42Z
dc.date.issued2014
dc.identifierDrug Development and Industrial Pharmacy, Volumen 40, Issue 5, 2018, Pages 577-578
dc.identifier15205762
dc.identifier03639045
dc.identifier10.3109/03639045.2014.892961
dc.identifierhttps://repositorio.uchile.cl/handle/2250/166188
dc.description.abstractDuring the past years, buccal drug delivery has attracted the attention of researchers looking for alternative delivery routes of administration. As an alternative to oral drug delivery, the buccal mucosal route avoids the passage through the acidic gastric environment, intestinal and bacterial enzymatic activity, absorption issues associated with the intestinal epithelium (e.g. P-glycoprotein efflux), and the first pass metabolism of the liver. Therefore, the buccal route could be a good delivery route for macromolecules and other drugs not compatible with the gastrointestinal tract environment. This "Buccal Drug Delivery" special edition of Drug Development and Industrial Pharmacy aims to bring together a range of different aspects relevant to the growing field of buccal drug delivery. The special edition includes thorough reviews of the literature, as well as original research articles touching on most prominent features related to buccal drug delivery systems, such as the move towa
dc.languageen
dc.publisherInforma Healthcare
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile
dc.sourceDrug Development and Industrial Pharmacy
dc.subjectBuccal drug delivery
dc.subjectMacromolecule delivery
dc.subjectNanotechnology
dc.subjectPermeation enhancement
dc.subjectProtein and peptide delivery
dc.titlePreface for buccal drug delivery theme issue
dc.typeArtículo de revista


Este ítem pertenece a la siguiente institución